Rủi ro bệnh tim mạch liên quan đến mãn kinh
Tóm tắt
Bệnh tim mạch (CVD) là mối quan tâm lớn đối với phụ nữ bước vào giai đoạn mãn kinh. Môi trường hormon thay đổi khiến họ có nguy cơ mắc CVD cao hơn, do một loạt các yếu tố nguy cơ như béo phì nội tạng, rối loạn lipid máu gây xơ vữa, rối loạn trong việc kiểm soát glucose, bệnh gan nhiễm mỡ không do rượu và tăng huyết áp. Tuy nhiên, mối liên hệ độc lập giữa mãn kinh
Từ khóa
Tài liệu tham khảo
European Heart Network. European Cardiovascular Disease Statistics 2017 edition. Brussels, Belgium: European Heart Network, 2017. (available at: http://www.ehnheart.org/cvd-statistics/cvd-statistics-2017.html)
Maas AHEMRosano GCifkova RChieffo Avan Dijken DHamoda HKunadian VLaan ELambrinoudaki IMaclaran KCardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European Cardiologists, Gynaecologists, and Endocrinologists. European Heart Journal202142967–984. (https://doi.org/10.1093/eurheartj/ehaa1044)3349578710.1093/eurheartj/ehaa1044
Stevenson JCCollins PHamoda HLambrinoudaki IMaas AHEMMaclaran KPanay N. Cardiometabolic health in premature ovarian insufficiency. Climacteric202124474–480. (https://doi.org/10.1080/13697137.2021.1910232)3416979510.1080/13697137.2021.1910232
Harlow SDGass MHall JELobo RMaki PRebar RWSherman SSluss PMde Villiers TJ & STRAW + 10 Collaborative Group. Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology and Metabolism2012971159–1168. (https://doi.org/10.1210/jc.2011-3362)2234419610.1210/jc.2011-3362
Anagnostis PGoulis DG. Menopause and its cardiometabolic consequences: current perspectives. Current Vascular Pharmacology201917543–545. (https://doi.org/10.2174/1570161117999190228123237)3081607410.2174/1570161117999190228123237
Anagnostis PPaschou SAKatsiki NKrikidis DLambrinoudaki IGoulis DG. Menopausal hormone therapy and cardiovascular risk: where are we now?Current Vascular Pharmacology201917564–572. (https://doi.org/10.2174/1570161116666180709095348)2998465910.2174/1570161116666180709095348
Mauvais-Jarvis FManson JEStevenson JCFonseca VA. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocrine Reviews201738173–188. (https://doi.org/10.1210/er.2016-1146)2832393410.1210/er.2016-1146
Toth MJTchernof ASites CKPoehlman ET. Menopause-related changes in body fat distribution. Annals of the New York Academy of Sciences2000904502–506. (https://doi.org/10.1111/j.1749-6632.2000.tb06506.x)10865795
Abildgaard JPloug TAl-Saoudi EWagner TThomsen CEwertsen CBzorek MPedersen BKPedersen ATLindegaard B. Changes in abdominal subcutaneous adipose tissue phenotype following menopause is associated with increased visceral fat mass. Scientific Reports20211114750. (https://doi.org/10.1038/s41598-021-94189-2)3428530110.1038/s41598-021-94189-2
Price TMO'Brien SNWelter BHGeorge RAnandjiwala JKilgore M. Estrogen regulation of adipose tissue lipoprotein lipase – possible mechanism of body fat distribution. American Journal of Obstetrics and Gynecology1998178101–107. (https://doi.org/10.1016/s0002-9378(9870634-9)946581110.1016/S0002-9378(98)70634-9
Ferrara CMLynch NANicklas BJRyan ASBerman DM. Differences in adipose tissue metabolism between postmenopausal and perimenopausal women. Journal of Clinical Endocrinology and Metabolism2002874166–4170. (https://doi.org/10.1210/jc.2001-012034)1221386610.1210/jc.2001-012034
Xu YNedungadi TPZhu LSobhani NIrani BGDavis KEZhang XZou FGent LMHahner LDDistinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metabolism201114453–465. (https://doi.org/10.1016/j.cmet.2011.08.009)2198270610.1016/j.cmet.2011.08.009
Walton CGodsland IFProudler AJWynn VStevenson JC. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. European Journal of Clinical Investigation199323466–473. (https://doi.org/10.1111/j.1365-2362.1993.tb00792.x)840499810.1111/j.1365-2362.1993.tb00792.x
Yan HYang WZhou FLi XPan QShen ZHan GNewell-Fugate ATian YMajeti REstrogen improves insulin sensitivity and suppresses gluconeogenesis via the transcription factor FoxO1. Diabetes201968291–304. (https://doi.org/10.2337/db18-0638)3048726510.2337/db18-0638
Wu SIChou PTsai ST. The impact of years since menopause on the development of impaired glucose tolerance. Journal of Clinical Epidemiology200154117–120. (https://doi.org/10.1016/s0895-4356(0000284-5)1116652510.1016/S0895-4356(00)00284-5
Anagnostis PChristou KArtzouchaltzi AMGkekas NKKosmidou NSiolos PPaschou SAPotoupnis MKenanidis ETsiridis EEarly menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. European Journal of Endocrinology201918041–50. (https://doi.org/10.1530/EJE-18-0602)3040004710.1530/EJE-18-0602
Reckelhoff JFFortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension200443918–923. (https://doi.org/10.1161/01.HYP.0000124670.03674.15)1502393310.1161/01.HYP.0000124670.03674.15
Reckelhoff JFGender differences in hypertension. Current Opinion in Nephrology and Hypertension201827176–181. (https://doi.org/10.1097/MNH.0000000000000404)2940636410.1097/MNH.0000000000000404
Sherwood AHill LKBlumenthal JAJohnson KSHinderliter AL. Race and sex differences in cardiovascular alpha-adrenergic and beta-adrenergic receptor responsiveness in men and women with high blood pressure. Journal of Hypertension201735975–981. (https://doi.org/10.1097/HJH.0000000000001266)2830663310.1097/HJH.0000000000001266
Anagnostis PTheocharis PLallas KKonstantis GMastrogiannis KBosdou JKLambrinoudaki IStevenson JCGoulis DG. Early menopause is associated with increased risk of arterial hypertension: a systematic review and meta-analysis. Maturitas202013574–79. (https://doi.org/10.1016/j.maturitas.2020.03.006)3225296810.1016/j.maturitas.2020.03.006
Salpeter SRWalsh JMOrmiston TMGreyber EBuckley NSSalpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism20068538–554. (https://doi.org/10.1111/j.1463-1326.2005.00545.x)1691858910.1111/j.1463-1326.2005.00545.x
Anagnostis PStevenson JCCrook DJohnston DGGodsland IF. Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions. Maturitas20158162–68. (https://doi.org/10.1016/j.maturitas.2015.02.262)2580495110.1016/j.maturitas.2015.02.262
Anagnostis PStevenson JCCrook DJohnston DGGodsland IF. Effects of gender, age and menopausal status on serum apolipoprotein concentrations. Clinical Endocrinology201685733–740. (https://doi.org/10.1111/cen.13085)2708656510.1111/cen.13085
Tsimikas STest A. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. Journal of the American College of Cardiology201769692–711. (https://doi.org/10.1016/j.jacc.2016.11.042)2818351210.1016/j.jacc.2016.11.042
Anagnostis PKarras SLambrinoudaki IStevenson JCGoulis DG. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options. International Journal of Clinical Practice201670967–977. (https://doi.org/10.1111/ijcp.12903)2803242610.1111/ijcp.12903
Robeva RMladenovic DVeskovic MHrncic DBjekic-Macut JStanojlovic OLivadas SYildiz BOMacut D. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause. Maturitas202115122–30. (https://doi.org/10.1016/j.maturitas.2021.06.012)3444627510.1016/j.maturitas.2021.06.012
Venetsanaki VPolyzos SA. Menopause and non-alcoholic fatty liver disease: a review focusing on therapeutic perspectives. Current Vascular Pharmacology201917546–555. (https://doi.org/10.2174/1570161116666180711121949)2999288610.2174/1570161116666180711121949
Wang ZXu MHu ZShrestha UK. Prevalence of nonalcoholic fatty liver disease and its metabolic risk factors in women of different ages and body mass index. Menopause201522667–673. (https://doi.org/10.1097/GME.0000000000000352)2551398310.1097/GME.0000000000000352
Kannel WBHjortland MCMcNamara PMGordon T. Menopause and risk of cardiovascular disease: the Framingham study. Annals of Internal Medicine197685447–452. (https://doi.org/10.7326/0003-4819-85-4-447)97077010.7326/0003-4819-85-4-447
Gordon TKannel WBHjortland MCMcNamara PM. Menopause and coronary heart disease. The Framingham Study. Annals of Internal Medicine197889157–161. (https://doi.org/10.7326/0003-4819-89-2-157)67757610.7326/0003-4819-89-2-157
Colditz GAWillett WCStampfer MJRosner BSpeizer FEHennekens CH. Menopause and the risk of coronary heart disease in women. New England Journal of Medicine19873161105–1110. (https://doi.org/10.1056/NEJM198704303161801)357435810.1056/NEJM198704303161801
Muka TOliver-Williams CKunutsor SLaven JSFauser BCChowdhury RKavousi MFranco OH. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiology20161767–776. (https://doi.org/10.1001/jamacardio.2016.2415)2762719010.1001/jamacardio.2016.2415
Tao XYZuo AZWang JQTao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric20161927–36. (https://doi.org/10.3109/13697137.2015.1094784)2657601210.3109/13697137.2015.1094784
Roeters van Lennep JEHeida KYBots MLHoek A & collaborators of the Dutch Multidisciplinary Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. European Journal of Preventive Cardiology201623178–186. (https://doi.org/10.1177/2047487314556004)2533120710.1177/2047487314556004
Honigberg MCZekavat SMAragam KFinneran PKlarin DBhatt DLJanuzzi JLJrScott NSNatarajan P. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA20193222411–2421. (https://doi.org/10.1001/jama.2019.19191)3173881810.1001/jama.2019.19191
Anagnostis PGalanis PChatzistergiou VStevenson JCGodsland IFLambrinoudaki ITheodorou MGoulis DG. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis. Maturitas20179927–36. (https://doi.org/10.1016/j.maturitas.2017.02.009)2836486510.1016/j.maturitas.2017.02.009
ACOG committee opinion no. 556: postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstetrics and Gynecology2013121887–890. (https://doi.org/10.1097/01.AOG.0000428645.90795.d9)23635705
Stuenkel CADavis SRGompel ALumsden MAMurad MHPinkerton JVSanten RJ. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism20151003975–4011. (https://doi.org/10.1210/jc.2015-2236)2644499410.1210/jc.2015-2236
Anagnostis PBitzer JCano ACeausu IChedraui PDurmusoglu FErkkola RGoulis DGHirschberg ALKiesel LMenopause symptom management in women with dyslipidemias: an EMAS clinical guide. Maturitas202013582–88. (https://doi.org/10.1016/j.maturitas.2020.03.007)3220927910.1016/j.maturitas.2020.03.007
Grady DRubin SMPetitti DBFox CSBlack DEttinger BErnster VLCummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine19921171016–1037. (https://doi.org/10.7326/0003-4819-117-12-1016)144397110.7326/0003-4819-117-12-1016
Stampfer MJColditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine19912047–63. (https://doi.org/10.1016/0091-7435(9190006-p)182617310.1016/0091-7435(91)90006-P
Rossouw JEAnderson GLPrentice RLLaCroix AZKooperberg CStefanick MLJackson RDBeresford SAHoward BVJohnson KCRisks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA2002288321–333. (https://doi.org/10.1001/jama.288.3.321)1211739710.1001/jama.288.3.321
Manson JEChlebowski RTStefanick MLAragaki AKRossouw JEPrentice RLAnderson GHoward BVThomson CALaCroix AZMenopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA20133101353–1368. (https://doi.org/10.1001/jama.2013.278040)2408492110.1001/jama.2013.278040
Anderson GLLimacher MAssaf ARBassford TBeresford SABlack HBonds DBrunner RBrzyski RCaan BEffects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA20042911701–1712. (https://doi.org/10.1001/jama.291.14.1701)1508269710.1001/jama.291.14.1701
Lokkegaard EAndreasen AHJacobsen RKNielsen LHAgger CLidegaard Ø. Hormone therapy and risk of myocardial infarction: a national register study. European Heart Journal2008292660–2668. (https://doi.org/10.1093/eurheartj/ehn408)1882698910.1093/eurheartj/ehn408
Boardman HMHartley LEisinga AMain CRoqué i Figuls MBonfill Cosp XGabriel Sanchez RKnight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews201510 CD002229. (https://doi.org/10.1002/14651858.CD002229.pub4)
Hodis HNMack WJHenderson VWShoupe DBudoff MJHwang-Levine JLi YFeng MDustin LKono NVascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine20163741221–1231. (https://doi.org/10.1056/NEJMoa1505241)2702891210.1056/NEJMoa1505241
Schierbeck LLRejnmark LTofteng CLStilgren LEiken PMosekilde LKober LJensen JE. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012345 e6409. (https://doi.org/10.1136/bmj.e6409)23048011
Harman SMBlack DMNaftolin FBrinton EABudoff MJCedars MIHopkins PNLobo RAManson JEMerriam GRArterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals of Internal Medicine2014161249–260. (https://doi.org/10.7326/M14-0353)2506999110.7326/M14-0353
Hulley SGrady DBush TFurberg CHerrington DRiggs BVittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA1998280605–613. (https://doi.org/10.1001/jama.280.7.605)10.1001/jama.280.7.605
Panay NHamoda HArya RSavvas M & British Menopause Society andWomen’sHealth Concern. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause International20131959–68. (https://doi.org/10.1177/1754045313489645)2376131910.1177/1754045313489645
Schenck-Gustafsson KBrincat MErel CTGambacciani MLambrinoudaki IMoen MHTremollieres FVujovic SRozenberg SRees MEMAS position statement: managing the menopause in the context of coronary heart disease. Maturitas20116894–97. (https://doi.org/10.1016/j.maturitas.2010.10.005)2115634110.1016/j.maturitas.2010.10.005
Mikkola TSTuomikoski PLyytinen HKorhonen PHoti FVattulainen PGissler MYlikorkala O. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. Journal of Clinical Endocrinology and Metabolism20151004588–4594. (https://doi.org/10.1210/jc.2015-1864)2641496210.1210/jc.2015-1864
Asi NMohammed KHaydour QGionfriddo MRVargas OLProkop LJFaubion SSMurad MH. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Systematic Reviews20165 121. (https://doi.org/10.1186/s13643-016-0294-5)27456847
Stute PWildt LNeulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric201821111–122. (https://doi.org/10.1080/13697137.2017.1421925)2938440610.1080/13697137.2017.1421925
Slopien RWender-Ozegowska ERogowicz-Frontczak AMeczekalski BZozulinska-Ziolkiewicz DJaremek JDCano AChedraui PGoulis DGLopes PMenopause and diabetes: EMAS clinical guide. Maturitas20181176–10. (https://doi.org/10.1016/j.maturitas.2018.08.009)3031456310.1016/j.maturitas.2018.08.009
Mach FBaigent CCatapano ALKoskinas KCCasula MBadimon LChapman MJDe Backer GGDelgado VFerence BA2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal202041111–188. (https://doi.org/10.1093/eurheartj/ehz455)3150441810.1093/eurheartj/ehz455
SCORE2 Working Group and ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal2021422439–2454. (https://doi.org/10.1093/eurheartj/ehab309)34120177
SCORE2-OPWorking Group and ESC CardiovascularRisk Collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. European Heart Journal2021422455–2467. (https://doi.org/10.1093/eurheartj/ehab312)34120185
Visseren FLJMach FSmulders YMCarballo DKoskinas KCBack MBenetos ABiffi ABoavida JMCapodanno D2021 ESC guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal2021423227–3337. (https://doi.org/10.1093/eurheartj/ehab484)3445890510.1093/eurheartj/ehab484
Grundy SMStone NJBailey ALBeam CBirtcher KKBlumenthal RSBraun LTde Ferranti SFaiella-Tommasino JForman DE2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation2019139e1082–e1143. (https://doi.org/10.1161/CIR.0000000000000625)